Zomedica (ZOMDF) Gets a Buy from Noble Financial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2025
0mins
Source: Business Insider
Analyst Rating and Price Target: Noble Financial analyst Robert LeBoyer maintained a Buy rating on Zomedica, setting a price target of $0.25, while the company's shares currently trade at $0.03.
Financial Performance: Zomedica reported a quarterly revenue of $7 million with a GAAP net loss of $6.7 million for the quarter ending September 30, compared to last year's revenue of $6.35 million and a significantly smaller net loss of $491 thousand.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
